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Abstract
Introduction: Mesenchymal stem cells (MSCs) are multipotent cells able to differentiate into several mesenchymal
lineages, classically derived from bone marrow (BM) but potentially from umbilical cord blood (UCB). Although they
are becoming a good tool for regenerative medicine, they usually need to be expanded in fetal bovine serum
(FBS)-supplemented media. Human platelet lysate (HPL) has recently been proposed as substitute for safety
reasons, but it is not yet clear how this supplement influences the properties of expanded MSCs.
Methods: In the present study, we compared the effect of various media combining autologous HPL with or
without FBS on phenotypic, proliferative and functional (differentiation, cytokine secretion profile) characteristics of
human BM-derived MSCs.
Results: Despite less expression of adipogenic and osteogenic markers, MSCs cultured in HPL-supplemented media
fully differentiated along osteoblastic, adipogenic, chondrogenic and vascular smooth muscle lineages. The analyses
of particular specific proteins expressed during osteogenic differentiation (calcium-sensing receptor (CaSR) and
parathormone receptor (PTHR)) showed their decrease at D0 before any induction for MSC cultured with HPL
mostly at high percentage (10%HPL). The cytokine dosage showed a clear increase of proliferation capacity and
interleukin (IL)-6 and IL-8 secretion.
Conclusions: This study shows that MSCs can be expanded in media supplemented with HPL that can totally
replace FBS. HPL-supplemented media not only preserves their phenotype as well as their differentiation capacity,
but also shortens culture time by increasing their growth rate.
Introduction
Mesenchymal stem cells (MSCs) represent a rare popu-
lation of multipotent progenitors, initially described in
bone marrow (BM), giving rise to adipocytes, osteo-
blasts, chondrocytes, and vascular smooth muscle
(VSM)-like hematopoietic supportive stromal cells [1,2].
These cells are capable of multilineage differentiation
from a single cell [3,4] and in vivo functional reconstitu-
tion of injured tissues in preclinical [5] as well in clinical
[6] settings. Thereafter, MSCs have been described in
virtually all post-natal organs or tissues [7] but also in
fetal adnexa, including both umbilical cord blood [8,9]
and placenta [7,10,11]. Today, BM remains the principal
source of MSCs in studies investigating their potential
use in cell therapy, in spite of significant declines in cell
proliferation and differentiation capacity with advancing
age [12].
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including CD90 (Thy-1), CD166 (SB10/ALCAM), CD73
(SH3), and CD105 (SH2 and endoglin), and lack hema-
topoietic (such as CD45 or CD34) and endothelial (such
as CD31) markers and HLA-DR. However, significant
heterogeneity in the morphology, proliferation, and dif-
ferentiation potentials of MSCs has also been observed
[13]. Fetal bovine serum (FBS)-based medium is the
conventional medium for isolation and expansion of
MSCs and has been used in several clinical trials [6].
However, concerns over the safety of FBS-based culture
media have been raised because they can trigger adverse
responses [14,15]. Accordingly, to culture MSCs, some
trials have used media containing animal serum-free
substitutes with combinations of growth factors [16]. An
alternative is to supplement media with human blood-
derived platelet lysates or sera from autologous or allo-
genic donors [17-21] to create culture conditions that
more closely mimic the human environment. However,
it is not yet clear how these culture conditions influence
the phenotype and function of the expanded MSC
populations.
In the present study, we have tested different media,
including combinations of autologous human platelet
lysate (HPL) with or without FBS, in order to compare
phenotypic, proliferative, and functional characteristics
together with the cytokine secretion profile of human
MSCs derived from BM. We focused particularly on the
mesenchymal differentiation ability of MSCs expanded
in these different conditions.
Materials and methods
Mesenchymal stem cell expansion cultures from bone
marrow
BM cells (n = 13) were isolated from patients with nor-
mal BMs harvested from donors at the Bone Marrow
Graft National Center of Tunisia (Tarek, Ben Othman,
Tunis) or during orthopedic surgery (Philippe Rosset,
Orthopedics Department, Hôpital Trousseau, Tours).
The mean age of the donors was 33 ± 2 years (range of
16 to 41 years). Informed consent was obtained from all
o ft h ep a t i e n t s( aw r i t t e nc o n s e n tw a sp r o v i d e db yt h e
patients from Tours) in accordance with the national
ethical guidelines of each country.
Mononuclear cells (MNCs) were isolated from each
BM sample by loading onto Ficoll Hypaque solution (d
= 1.077). After centrifugation at 800g for 20 minutes at
room temperature, the MNC layer was removed from
the interphase and washed twice with phosphate-buf-
fered saline (PBS). Then they were seeded into uncoated
T25 or T75 flasks (Becton, Dickinson and Company,
Franklin Lakes, NJ, USA) at a cell concentration of 1 ×
10
5 cells per square centimeter for BM cells. Cells were
cultured in basic growth medium (BGM) consisting of
alpha-minimum essential medium (a-MEM) (Invitrogen
Corporation, Carlsbad, CA, USA) with 100 U/mL peni-
cillin, 0.1 mg/mL streptomycin (Invitrogen), 2 mM L-
glutamine (Invitrogen), 0.025 mg/mL amphotericin B
(Invitrogen) with various supplements to obtain the four
following expansion culture media: (M1) BGM with 10%
(vol/vol) of prescreened FBS (HyClone, Thermo Fisher
Scientific Inc., Waltham, MA, USA) and 1 ng/mL fibro-
blast growth factor 2 (FGF2) (AbCys, Paris, France),
(M2) BGM with 10% FBS and 5% (vol/vol) HPL, (M3)
BGM with 10% HPL, and (M4) BGM with 5% HPL.
Cultures were maintained in a humidified atmosphere
with 5% CO2 at 37°C and the medium had been chan-
ged twice weekly thereafter. On reaching 60% to 80%
confluence, the adherent cells were detached after treat-
ment with 0.05% (vol/vol) trypsin/1 mM ethylenediami-
netetraacetic acid (EDTA) solution (Invitrogen) and
reseeded at 10
3 cells per square centimeter. All of the
studies, except for cell proliferation and CFU-F assays,
had been performed after two passages (P2).
Human platelet lysate preparation
HPLs were prepared in accordance with a method pre-
viously described [19]. Briefly, they were obtained from
different platelet apheresis collections performed at the
National Blood Transfusion Center of Tunis (Tunisia).
HPLs from at least 10 donors were pooled and, after
elimination of remaining platelet bodies by centrifuga-
tion (1,400g for 20 minutes), were frozen at -80°C to be
subsequently used as FBS or growth factor substitute or
both.
Phenotypic analysis of mesenchymal stem cells by flow
cytometry
T h ep h e n o t y p i ca n a l y s i sw a sp e r f o r m e da f t e rP 2b y
incubation of the adherent cells with monoclonal anti-
bodies. Cultures were washed twice with PBS, and cells
were subsequently detached by enzymatic treatment by
using 0.05% trypsin/EDTA solution (Invitrogen) for 5
minutes at 37°C. Cells were washed and adjusted to 1 ×
10
6/mL in PBS. Cell suspensions (100 mL) were incu-
bated with 5 μL of fluorescein isothiocyanate (FITC)-,
phycoerythrin (PE)-, or peridinin chlorophyll protein
(PerCP)-conjugated IgG1 monoclonal antibodies (Bec-
ton, Dickinson and Company) for 30 minutes at room
temperature in the dark. They were CD45-PerCP,
CD14-PE, CD31-PE, CD146-FITC, CD34-PE, CD90-
FITC or CD90-PE, CD105-PE, CD106-PE, and CD133-
PE (BD Biosciences, San Jose, CA, USA). Nonspecific
background was evaluated by parallel staining with iso-
type-matched IgG1-FITC, IgG1-PerCP, and IgG1-PE.
Cells were fixed with 4% paraformaldehyde and analyzed
by using a Becton, Dickinson and Company flow cyt-
ometer (FACScalibur
™ or FACS Canto II
™).
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stem cells
Osteogenic induction
At 50% confluence, the cells were cultured for 14 days
in Dulbecco’s modified Eagle’s medium-high glucose
(DMEM-HG) (with 4.5 g/L glucose) containing 2% FBS,
0.1 μM dexamethasone (Sigma-Aldrich, St. Louis, MO,
USA), 2 mM b-glycerolphosphate (Sigma-Aldrich), and
100 μM ascorbate-2-phosphate (Sigma-Aldrich) with
medium changes every 3 days. After 2 weeks of induc-
tion, the cells were stained in accordance with von
Kossa and Alizarin red methods to detect the presence
of calcium deposition into osteocytes.
Adipogenic induction
The adipogenic induction medium consisted of DMEM-
LG (with 1 g/L glucose) supplemented with 20% FBS, 1
μM/L dexamethasone, 0.5 mmol/L isobutylmethyl-
xanthine (Invitrogen), and 60 μmol/L indomethacin
(Sigma-Aldrich). Adipogenic differentiation was evalu-
ated after 2 weeks of induction by the cellular accumu-
lation of neutral lipid vacuoles that were stained with
Nile red (Sigma-Aldrich) and observed by fluorescent
microscopy.
Chondrogenic induction
Chondrogenic differentiation was obtained in micropel-
lets (3 × 10
5 cells per pellet) incubated in tubes at 37°C
for 21 days in 500 μL of chondrogenic medium consist-
ing of DMEM-HG with 0.1 μM dexamethasone (Sigma-
Aldrich), 1 mM sodium pyruvate, 170 μM ascorbic acid-
2-phosphate (Sigma-Aldrich), 350 μM proline (Sigma-
Aldrich), 1X insulin-transferrin-selenium (Cambrex, East
R u t h e r f o r d ,N J ,U S A ) ,a n d10 ng/mL transforming
growth factor-beta-1 (TGF-b1) (AbCys). Medium was
changed every 4 days. Chondrogenic differentiation was
evaluated after 21 days of induction. The presence of
glycosaminoglycans in cell pellets was revealed by Alcian
blue and Toluidine blue staining. On the 21st day, pel-
lets were fixed for 48 hours in 4% paraformaldehyde
and embedded in paraffin. Sections (4 μmt h i c k )w e r e
rehydrated in 70%, 90%, and 100% xylene and ethanol.
For Alcian blue staining, slides were incubated for 10
minutes in a 1:1 mixture of 3% (vol/vol) Alcian blue
8GX (Sigma-Aldrich) solution in distilled water and 3%
(vol/vol) methanol. For Toluidine blue staining, slides
were incubated for 10 minutes in a 1% Toluidine blue
(Sigma-Aldrich) (vol/vol) solution in 70% ethanol.
Vascular smooth muscle induction
VSM differentiation was obtained in McCoy’s5 Am e d -
ium supplemented with 12.5% FBS, 12.5% horse serum
(Invitrogen), 2 mM L-glutamine, 0.8 mM L-serine, 0.15
mM L-asparagine, 1 mM sodium pyruvate, 5 mM
sodium bicarbonate, 1 μM hydrocortisone and 0.25 μg/
mL amphotericin B. Medium was changed every 4
days. VSM differentiation was evaluated after 3 weeks
of induction. MSCs were fixed by using 4% parafor-
maldehyde and incubated with primary antibodies
against rat alpha smooth muscle actin (ASMA) (clone
1A4, mouse anti-human, -mouse, -rat; Sigma-Aldrich)
at 4°C for 12 hours. The antigen-antibody reaction was
detected by using a specific anti-mouse secondary anti-
body coupled to FITC (Alexa Fluor 488; Invitrogen)
dyes, and the reaction was visualized by fluorescent
microscopy.
Mesenchymal stem cell expression of differentiation
markers by RT-PCR and Western blotting
For reverse transcription-polymerase chain reaction
(RT-PCR), total RNA was extracted from MSCs at 90%
confluence by using TRIZOL reagent (Invitrogen) in
accordance with the instructions of the manufacturer.
Reverse transcription was carried out by using Prime-
Script
™RTase (Takara, Kyoto, Japan), and the cDNA
fragments were amplified by using RNase Inhibitor
(Takara). After denaturation at 65°C for 5 minutes,
amplification was carried out by 30 cycles at 30°C for 10
minutes, 42°C for 60 minutes, and 95°C for 5 minutes.
Primers used are shown in Table 1. The expression of
the following genes was studied: alkaline phosphatase
(ALP) nd Runt-related transcription factor 2 (RUNX2)
for osteogenic pathway, peroxisome proliferator-acti-
vated receptor-gamma (PPARg) and lipoprotein lipase
(LPL) for adipogenic pathway, and ASMA for VSM dif-
ferentiation. Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) gene expression was used as a control.
Table 1 Sequences of the primers used in reverse transcription-polymerase chain reaction study
Construct Forward sequence Reverse sequence
GAPDH 5’- AATCCCATCACCATCTTCCAGG-3’ 5’-AGAGGCAGGGATGATGTTCTGG-3’
ALP 5’-CTGGACCTCGTTGACACCTG-3’ 5’-GACATTCTCTCGTTCACCGC-3’
RUNX2 5’-AACTTCCTGTGCTCGGTGCTG-3’ 5’-GGGGAGGATTTGTGAAGACGG-3’
LPL 5’-AAAGCCCTGCTCGTGCTGAC-3’ 5’-TAAACCGGGCCACATCCTGT-3’
PPARg 5’-GGAGAAGCTGTTGGCGGAGA-3’ 5’-TCAAGGAGGCCAGCATTGTG-3’
ASMA 5’-TCATGATGCTGTTGTAGGTGGT-3’ 5’-CTGTTCCAGCCATCCTTCAT-3’
ALP, alkaline phosphatase; ASMA, alpha smooth muscle actin; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; LPL, lipoprotein lipase; PPARg, peroxisome
proliferator-activated receptor-gamma; RUNX2, Runt-related transcription factor 2.
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cycler (Takara).
For Western blotting, MSCs were harvested at 90%
confluence. Cell pellets were resuspended in lysis buffer
( 8Mu r e a ,2Mt h i o u r e a ,2 %C H A P S ,1 %N P - 4 0 ,2m M
TBP, 16 Protease Inhibitor Mix, 16 Nuclease Mix, 1
mM PMSF, and 2% IPG buffer) and put on ice for 45
minutes. They were then centrifuged at 14,000g for 15
minutes at 4°C. The supernatant was collected and
stored at -80°C. The protein concentration of samples
was determined by means of Bradford’sm e t h o d( B i o -
Rad Laboratories, Inc., Hercules, CA, USA). Equal
amounts of cell extracts and of conditioned media were
separated by SDS-PAGE (12%) and transferred to poly-
vinylidene difluoride (PVDF) membranes. Membranes
were blocked with 5% skim milk for an hour and left to
react with anti-human b-actin (clone AC-15, mouse
IgG1; Sigma-Aldrich) as a positive control, anti-human
leptin (monoclonal; R&D Systems, Inc., Minneapolis,
MN, USA, reference number 398), anti-human calcium-
sensing receptor (CaSR) (monoclonal; AbCam, Cam-
bridge, UK, reference number ab 3513), anti-human
parathormone receptor (PTHR) (mouse monoclonal
anti-human; Novocastra, part of Leica Microsystems,
Wetzlar, Germany), anti-human ASMA (clone 1A4,
mouse anti-human, -mouse, -rat; Sigma-Aldrich), and
anti-human transgelin (SM22a) (mouse monoclonal
anti-human; Novocastra). Antibody binding was revealed
by incubation with the corresponding HRP-linked IgG
(horseradish peroxydase; Bio-Rad Laboratories, Inc.) and
the ECL+ Western blotting detection kit (Amersham
Biosciences, now part of GE Healthcare, Little Chalfont,
Buckinghamshire, UK). Chemiluminescence was
detected and measured with a Chemi-Smart 2000
™ Ima-
ger (Vilber Lourmat, Marne-la-Vallée, France).
Clonogenic and proliferative capacities of mesenchymal
stem cells
Colony-forming unit-fibroblast assays
CFU-F assays were performed to evaluate the clonal
expansion capacity of the MSCs initially cultured in the
six different media. For the optimal counting of colo-
nies, MNCs derived from BM were seeded at 10
5 cells
per square centimeter in T25 flasks in duplicate. Flasks
were incubated in a humidified atmosphere with 5%
CO2 at 37°C. The medium was completely renewed
every 3 days. Cell clusters containing more than 50 cells
were scored on day 10 as CFU-F colonies by using an
inverted microscope. Cloning efficiency was considered
as CFU-F counts per 10
6 MNCs plated.
Population doubling time
T ot e s tt h er o l eo fc u l t u r ec o n d i t i o n so nM S Ce x p a n -
sion, MSCs were cultured in each of the six expansion
media for two passages (P2) before analysis. Population
doubling times (PDTs) were calculated between P1 and
P2 as t/n, where t is the duration of culture in days and
n is the number of population doublings calculated by
using the formula n =( l o gN h - log Ni)/log 2, where Nh
is the number of cells harvested at the time of counting
at P2 and Ni is the number of cells initially plated at
P1).
Cytokine secretion capacity of mesenchymal stem cells
C y t o k i n e sw e r ed e t e c t e di ns u p e r n a t a n t so fM S C sc u l -
tured in different expansion media and were collected at
P2. Concentrations of IL-6, IL-8, vascular endothelial
growth factor (VEGF), FGF2, granulocyte colony-stimu-
lating factor (G-CSF), granulocyte-macrophage colony-
stimulating factor (GM-CSF), and RANTES (regulated
on activation normal T cell expressed and secreted)
were simultaneously evaluated by using a commercially
available multiplex bead-based immunoassay (Bio-Plex
™
cytokine assay system; BD Biosciences).
Statistical analysis
Statistical analysis was performed by using the STAT-
GRAPHICS Centurion XVI program version 16.0.08
(StatPoint Technologies Inc., Warrenton, VA, USA). A
one-way analysis of variance and Newman-Keuls multi-
ple range test were carried out to compare value distri-
butions. Significant difference between group values was
considered when P value was less than 0.05. Indicated
values are mean ± standard error mean.
Results
Phenotypic characteristics of mesenchymal stem cells
cultured in various expansion media
Morphological analysis
Adherent cell populations from the MNC fraction of
human BM samples were generated by expansion cul-
ture by using four different media: (M1) BGM with 10%
FBS and 1 ng/mL FGF2, (M2) BGM with 10% FBS and
5% HPL, (M3) BGM with 10% HPL, and (M4) BGM
with 5% HPL. After 2 weeks of culture, an adherent and
stable cell layer was obtained from BM-derived MNCs
with all media (n = 13). Figure 1 shows a particular
morphology of MSCs cultured with HPL (M3 and M4).
In fact, the layer of MSCs appears with many spaces
between the cells in comparison with standard medium
(M1), in which we have one layer of very confluent
MSCs (Figure 1).
Immunophenotype analyzed by flow cytometry
MSCs from different BM samples were characterized by
flow cytometry with a panel of six markers at P2 after
culture in media containing HPL (M2, M3, M4) or not
containing HPL (M1). All BM derived-MSCs were nega-
tive for hematopoietic markers CD34, CD14, and CD45
( F i g u r e2 A )a n dw e r ec o n s i s t e n t l yp o s i t i v ef o rt h eM S C
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Page 4 of 14markers CD106, CD73, CD90, and CD105, regardless of
the expansion medium used (Figure 2B). For immaturity
markers, expression of CD49a was low and CD133 was
undetectable without any influence of medium type.
Our data did not show any statistical difference between
the four culture conditions.
Mesenchymal differentiation capacity of mesenchymal
stem cells assessed by specific staining in different
culture conditions
The influence of HPL in expansion media on further
differentiation potential of MSCs toward osteogenic, adi-
pogenic, chondrogenic, and VSM lineages after appro-
priate induction was investigated at the second passage
(P2) and specific staining (Figure 3). BM cells grown in
HPL or FBS deposited an extensive mineralized matrix
when cultured for 2 weeks in osteogenic medium, as
demonstrated by strong Alizarin red and von Kossa
staining. These cells also efficiently differentiated into
the adipogenic lineage, as indicated by Nile red staining
of lipid droplets in the cytoplasm following culture in
adipogenic medium except when a high concentration
(10%) of HPL was used (M3). After chondrogenic differ-
entiation for 3 weeks, MSCs displayed a typical chon-
droblast shape, as indicated by the deposition of specific
glycosaminoglycans seen after Alcian blue and O Safra-
nin staining, irrespectively of the expansion media used
previously (M1, M2, M3, and M4).
Osteogenic, adipogenic, and vascular smooth muscle
gene expression assessed by RT-PCR analysis in
mesenchymal stem cells
Gene expression was analyzed by RT-PCR after MSC
amplification (P1) in HPL- and FBS-supplemented
m e d i ab e f o r e( d a y0 ,o rD 0 )a n da f t e rd i f f e r e n t i a t i o n
(day 14, or D14) from four different MSCs. We tested
the expression of two osteogenic (O)-specific genes
(ALP and RUNX2), two adipogenic (A)-specific genes
(PPARg and LPL), and one VSM gene (ASMA)b e f o r e
differentiation. mRNA expressions of ALP, RUNX2,
PPRg,a n dASMA were decreased in M2 (10% FBS + 5%
HPL) and M3 (10% HPL) media in comparison with
standard M1 medium (10% FBS + 1 ng/mL FGF2) or
M4 medium containing only 5% HPL (Figure 4A). At
D0, HPL seems to decrease the osteogenic markers.
Concerning the adipogenic markers, PPARg decreased at
D0 when the HPL was added to the culture medium
(M2, M3, and M4) in comparison with standard med-
ium (M1). Also, in M2 (10% FBS + 5% HPL), we showed
a decrease of PPARg after adipogenic induction at D14.
                       M1                                         M2 
 
                       M3                                          M4 

Figure 1 Morphological characterization of bone marrow (BM)-derived mesenchymal stem cells (MSCs) cultured in different media at
passage 2 (P2). The media were M1 (10% FBS + FGF2), M2 (10% FBS + 5% HPL), M3 (10% HPL), and M4 (5% HPL). Bar represents 100 μm. FBS,
fetal bovine serum; FGF2, fibroblast growth factor 2; HPL, human platelet lysate. Representative results from 13 experiments are shown.
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                  Control                       M1                          M2                           M3                         M4 
                                                     
                                                        
                                                        
                                                       
CD34 
CD45 
CD133 
CD14 
                 Control                      M1                           M2                          M3                          M4 
                                                    
                                                     
                                                      
                                                    
CD49e 
CD105 
CD73 
CD90 
CD106 
Figure 2 Representative flow cytometry analysis of BM-derived MSCs cultured in different expansion media. Comparison of membrane
antigen expression of MSCs cultured at passage 2 (P2) in four different media: M1 (10% FBS + FGF2) (n = 4), M2 (10% FBS + 5% HPL) (n = 5),
M3 (10% HPL) (n = 6), and M4 (5% HPL) (n = 5). The histogram plots represent flow cytometry analysis of the cells with directly labeled
monoclonal antibodies (histograms colored inside) or exposed to isotype-matched non-immune directly labeled immunoglobulins (IgG1FITC,
IgG1PE, and IgG1PerCP). MSCs were negative for hematopoietic markers CD45, CD34, CD133, and CD14 (A) but were positive for CD90, CD73,
CD105, and CD106 and weakly positive for CD49e (B). (A) Hematopoietic and immaturity markers. (B) Stromal cell markers.
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protein expression assessed by Western blotting in
mesenchymal stem cells
Proteins specific of osteogenic, VSM, and adipogenic
lineages were identified in MSCs in different culture
conditions. MSCs cultured in 10% FBS + 5% HPL med-
i u m( M 2 )d i s p l a y e dt h es a m ee xpression profile for the
osteogenic markers CaSR and PTHR as in standard
medium (M1) before (D0) and after (D14) differentia-
tion. In contrast, the expression of these proteins was
clearly decreased in 10% HPL (M3) and 5% HPL (M4)
media. We noted the same results with the adipogenic
marker (Leptin) (Figure 5). The expression of VSM dif-
ferentiation proteins (ASMA and SM22a) seems not to
be affected by the type of expansion medium (Figure 5).
Clonogenic and proliferative capacities of mesenchymal
stem cells cultured in various expansion media
Colony-forming unit-fibroblast assays
MNCs initially seeded in the four expansion media were
assayed for CFU-F. No clear difference was observed in
colony counts for 10
6 BM MNCs plated when compar-
ing the output in FBS- and HPL-supplemented expan-
sion culture media (Figure 6). HPL-supplemented
cultures resulted in significantly larger colonies, which
appeared densely packed with very small spindle-shaped
cells compared with colonies in FBS cultures formed by
only loosely connected cells (Figure 3: M2-M3 versus
M1). The growth-promoting effect of HPL on CFU-F
was associated with increased density of total cells at
confluence.
Population doubling time
Expansion rates of MSCs were very different when cul-
tured in media supplemented with or without HPL (Fig-
ure 7). Thus, PDTs of MSCs cultured in regular
medium containing FBS with FGF2 (M1) remained
longer than in HPL-supplemented cultures (M2: 5.6 ±
0.5 days; M3: 5.8 ± 1.03 days; and M4: 3.8 ± 0.7 days; P
< 0.0007).
Cytokine expression profile of mesenchymal stem cells
Cytokine expression profile of MSCs from BM was com-
pared by using the Bio-Plex
™ cytokine assay system (BD
Biosciences) in accordance with the instructions of the
manufacturer. MSC supernatants were collected after 3
to 4 days of culture at P2 with M1, M2, M3, and M4
for BM. This technique allowed the simultaneous mea-
surement of concentrations of several cytokines that
included FGF2, RANTES, VEGF, IL-6, IL-8, G-CSF, and
GM-CSF. In parallel to MSC supernatants, background
cytokine concentrations were evaluated in each corre-
sponding medium used (M1, M2, M3, and M4). In
these growth media, all of the cytokines - except for
RANTES, which was present at high concentrations in
HPL-containing media (M2, M3 and M4) but was at
very low concentrations in standard medium M1
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Figure 3 Osteogenic, chondrogenic, adipogenic, and vascular smooth muscular differentiation capacity assessed by staining of BM-
derived MSCs cultured in different expansion media. The media are M1 (10% FBS + FGF2), M2 (10% FBS + 5% HPL), M3 (10% HPL), and M4
(5% HPL). Results are of one representative experiment. A, adipogenic differentiation; ASMA, alpha smooth muscle actin; C, chondrogenic
differentiation; D0, before differentiation; D14, after 14 days of differentiation; O, osteogenic differentiation; VSM, vascular smooth muscle.
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Page 7 of 14(lacking HPL) - were undetectable. MSC supernatants
contained IL-6, IL-8, and VEGF at variable levels
according to the different expansion culture conditions.
Thus, the presence of HPL appeared to increase IL-6
and IL-8 concentrations (Figure 8A, B), while FGF2, G-
CSF, and GM-CSF remained undetectable in all culture
conditions.
Discussion
This study points out the interest in HPL as a replace-
ment for FBS in culture media for expansion of human
BM MSCs. Thus, HPL-containing media not only pre-
serve their phenotype as well as their differentiation
capacity but also shorten culture time by increasing
their growth rate. Nevertheless, some differences exist in

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Figure 4 mRNA expression by BM-derived MSCs cultured in different expansion media. Reverse transcription-polymerase chain reaction
(RT-PCR) for positive control GAPDH (A), osteogenic (B), adipogenic (C), and vascular smooth muscle (D) gene expression of BM-derived MSCs
cultured in four media: M1 (10% FBS + FGF2), M2 (10% FBS + 5% HPL), M3 (10% HPL), and M4 (5% HPL). Total RNA was extracted from
undifferentiated and differentiated MSCs previously cultured in four expansion media (M1, M2, M3, and M4). The cDNA obtained was used for
PCR assays to evaluate the expression of the different genes studied. One representative experiment out of four experiments is shown. For
GAPDH gene expression (A): 1, at D0 before any differentiation; 2, after osteogenic differentiation (D14); 3, after adipogenic differentiation (D14);
4, after vascular smooth muscle differentiation (D14). For osteogenic (RUNX2 and ALP) (B), adipogenic (PPARg and LPL) (C), and vascular smooth
muscle (ASMA) (D) gene expression: 1, D0 before any differentiation; 2, after differentiation induction (D14). ALP, alkaline phosphatase; ASMA,
alpha-smooth muscle actin; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; LPL, lipoprotein lipase; PPARg, peroxisome proliferator-activated
receptor-g; RUNX2, runt-related transcription factor 2.
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Page 8 of 14terms of cytokines produced, suggesting functional dif-
ferences between MSCs expanded in media supplemen-
ted with HPL and FBS. This has to be considered for
particular clinical applications.
The possibility to use animal serum-free culture media
has been reported in several recent studies by substitut-
ing FBS with human-derived supplements such as HPL
or human serum [17-25]. In the present study, MSC
expansions were performed in three different HPL-sup-
plemented media consisting of BGM (a-MEM) with
(M2) or without (M3 and M4) FBS and compared with
the standard medium devoid of HPL (M1). M1 (supple-
mented with 10% FBS + 1 ng/mL FGF2) represents the
reference medium for MSC expansion in our laboratory.
In M2, FGF2 was replaced by 5% HPL (vol/vol). FBS-
free M3 and M4 media were supplemented with 10%
and 5% HPL, respectively. The four media were used for
expansion of BM-derived MSCs to study the influence
of HPL on MSC functions. Our study clearly showed
that the presence of HPL is necessary for MSC growth
to substitute the standard expansion medium containing
the FBS.
The addition of HPL in expansion media did not
modify the immunophenotype of MSCs, irrespectively of
the amounts used and of the presence or absence of
FBS. These cell display a typical feature of MSCs bear-
ing CD73, CD90, CD105, and CD106 and lacking the
hematopoietic markers CD45, CD34, and CD14. Imma-
turity marker expression did not vary with low levels of
CD49a, and undetectable levels of CD133. This lack of
consistent immunophenotypic changes of MSCs cul-
tured in HPL-supplemented media has been reported
[8,19-21,25,26].
We demonstrated that adherent cells expanded in
HPL-supplemented media were multipotent since they
were able to differentiate toward four mesenchymal
pathways (adipogenic, osteogenic, chondrogenic, and
VSM). Thus, we confirm (in addition to VSM pathway)
Figure 5 Western blot analysis showing differentiation markers of osteogenic, vascular smooth muscle, and adipogenic lineages
expressed by BM-derived MSCs cultured in different expansion media. The media are M1 (10% FBS + FGF2), M2 (10% FBS + 5% HPL), M3
(10% HPL), and M4 (5% HPL). The experiments were performed in triplicate, and one representative blot is shown here. Beta-actin expression
was used as positive control. Osteogenic proteins studied are calcium-sensing receptor (CaSR) and parathormone receptor (PTHR). Adipogenic
protein studied is Leptin. Vascular smooth muscle proteins studied are smooth muscle 22alpha (SM22a) and alpha-smooth muscle actin (ASMA).
D0, day 0 (before induction); D14, day 14 (after induction).
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Page 9 of 14the data of previous studies [19,21-23,27]. However, in
M3 containing 10% HPL, MSCs displayed a weak adipo-
genic differentiation with only a few vesicular adipocytes
stained with Nile red.
To assess more precisely the differentiation state of
MSCs after expansion in the different media studied
and their subsequent differentiation potential, we stu-
died the expression of several differentiation genes by
 
n=6  n=5 n=7 
n=5 
#  #  # 
# 
Figure 6 Effect of expansion media on colony-forming unit-fibroblast (CFU-F) counts per 10
6 bone marrow mononuclear cells.T h e
media are M1 (10% FBS + FGF2), M2 (10% FBS + 5% HPL), M3 (10% HPL), and M4 (5% HPL). Data shown represent mean ± standard error of
the mean from the indicated number of experiments.
#No significant difference; P > 0.05.
 
     
n=6 
n=6 
n=4 
* 
   # 
 # 
# 
n=6 
Figure 7 Population doubling time (PDT) in days of adherent cells cultured in different expansion media between passage 1 (P1) and
passage 2 (P2). The media are M1 (10% FBS + FGF2), M2 (10% FBS + 5% HPL), M3 (10% HPL), and M4 (5% HPL). Data shown represent mean ±
standard error of the mean from the indicated number of experiments. *Significant difference; P < 0.0007.
#No significant difference; P > 0.05.
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Page 10 of 14RT-PCR and of proteins by Western blotting for adipo-
genic, osteogenic, and VSM lineages. These analyses
revealed that BM-derived MSCs expanded in all media
already express (at both mRNA and protein levels) all of
these differentiation markers without any differentiation
induction. These data are consistent with those of
Delorme and colleagues who demonstrated that non-
differentiated human BM-derived MSCs are character-
ized by lineage priming [28].
However, these markers decreased or even seemed to
be absent at D0 (before induction) in the media contain-
ing the HPL as a supplement (M2, M3, and M4).
This includes early-appearing genes for adipogenic
(PPARg and LPL), osteogenic (RUNX2 and ALP), and
 
 
Figure 8 Cytokine expression profile of mesenchymal stem cells (MSCs) cultured in different expansion media. Cytokine concentrations
(expressed in picograms per 10
6 cells) were evaluated in MSC supernatants at passage 2 (P2) after culture in M1 (10% FBS + FGF2) (n = 4), M2
(10% FBS + 5% HPL) (n = 6), M3 (10% HPL) (n = 4), and M4 (5% HPL) (n = 3). (A) IL-6 (*P = 005; **P = 0.01). (B) IL-8 (*P < 0.05). (C) VEGF (*P <
0.01). IL, interleukin; VEGF, vascular endothelial growth factor.
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Page 11 of 14VSM (ASMA) lineages but also specific proteins of adi-
pogenic (Leptin), osteogenic (CaSR and PTH), and VSM
(ASMA and SM22a) lineages. This HPL-induced differ-
entiation defect of MSCs is rather due to an inhibition
of adipogenic and osteogenic marker expression than to
an expansion of a more immature MSC subpopulation
as indicated by immunophenotypic analysis. Neverthe-
less, this inhibitory effect had no impact on real multi-
potency of MSCs, since they fully differentiated further
toward adipogenic, osteogenic, chondrogenic, and VSM
lineages.
To complete these phenotypical and functional stu-
dies, we investigated clonogenic and proliferative capaci-
ties of MSCs according to the presence or absence of
HPL in expansion media. Clonogenic efficiency was
evaluated within the MNC fraction initially seeded in
t h ef o u rd i f f e r e n tm e d i af r o mB M .H P L( a l o n eo rc o m -
bined with FBS) did not affect the recruitment of the
clonogenic MSC fraction with values ranging from 80 to
100 CFU-F per 10
6 MNCs. This suggests that MSCs
grown in such media are functionally close to those
obtained in regular media (devoid of HPL). This paral-
lels the lack of immunophenotypic changes for imma-
ture populations (CD49a and CD133) known to contain
the clonogenic cell population [29,30].
Although HPL-supplemented media did not modify
clonogenic efficiency of BM-derived MNCs colonies
appeared larger than in regular medium and were
formed by small, densely packed, spindle-shaped cells.
Such a growth-promoting effect on formed colonies sug-
gests an impact of HPL on the proliferative capacity of
MSCs. This was confirmed by calculating the PDT of
MSCs between passage 1 and passage 2; the PDT was
considerably shortened in all of the media containing
HPL. This effect can be attributed to HPL itself since it
was not enhanced by the presence of FBS. The only
replacement of FBS by 5% HPL in BGM led to a maxi-
mal effect with about a fourfold reduction of PDT.
Thus, the use of HPL can be of particular interest in
clinical applications to shorten human MSC culture
duration and then minimize the risk of entering senes-
cence and transformation [31]. Higher growth-promot-
ing activity of human substitutes for FBS (particularly
HPL) on MSCs has been pointed out by several authors
[12,18-20,22,24,27,32,33]. Bieback and colleagues [21]
showed that only HPL-supplemented medium, in con-
trast to human sera- and platelet-enriched plasma, is
able to increase the growth rate of MSCs cultured in
FBS-supplemented medium. The high levels and num-
bers of platelet-derived growth factors contained in HPL
are likely to be responsible for the accelerated growth
rate of MSCs that could act in synergy with each other.
Many growth factors have been found in platelet con-
centrates [27,34]. Among these, TGF-b, PDGF, and
FGF2 have been shown to be critical for both differen-
tiation and proliferation of MSCs [35].
In addition, we assessed the cytokine secretion pro-
file of MSCs expanded in regular medium (M1) and in
three HPL-supplemented media (M2, M3, and M4).
We used a multiplex bead-based immunoassay array to
simultaneously measure concentrations of seven cyto-
k i n e s( F G F 2 ,R A N T E S ,V E G F ,I L - 6 ,I L - 8 ,G - C S F ,a n d
GM-CSF) in MSC supernatants in comparison with
corresponding media. All MSC supernatants contained
IL-6, IL-8, and VEGF at variable levels according to
the different expansion culture conditions, whereas
FGF2, G-CSF, and GM-CSF remained undetectable in
supernatants in all culture conditions of MSCs. The
presence of HPL increased IL-6 and IL-8 concentra-
t i o n s ,i np a r t i c u l a r ,a t1 0 % .V a r i a t i o n so fR A N T E S
expression cannot be evaluated, because of the high
level of this chemokine in HPL-supplemented media,
whereas consistent baseline levels were found in super-
natants of MSCs cultured in regular medium. In fact,
the expression cytokine profile in MSCs cultured in
regular medium is now well established. We previously
reported by mRNA array that MSCs express a number
of tyrosine kinase receptor cytokines, including VEGF,
Ang-1, PDGFA, FGF1 and 2, EGF, IGF-1, and HGF,
but also a number of CC and CXC chemokines,
including RANTES, MCP-1, GRO alpha and beta, IL-8,
and SDF-1 [36]. Similar results were found in other
studies at the protein level by large-scale analysis
[37,38]. Although constitutive expression of the hema-
topoietic growth factors G-CSF and GM-CSF, has also
been reported in other studies [37,39], these growth
factors were not found in the present study. { This
may reflect technical differences with lower sensitivity
(but higher specificity) of the Bio-Plex
™ technique, as
indicated by the lack of detection of cytokines (except
for RANTES) in HPL-containing media. Otherwise, we
demonstrated here that secretion of both the pro-
inflammatory and hematopoietic cytokine IL-6 and the
chemokine IL-8 was increased in MSCs previously
expanded in HPL-supplemented medium, as described
elsewhere for IL-6 [21]. This indicates that HPL con-
tains strong inductors of such cytokines that could
minimize the anti-inflammatory activity of MSCs.
Conclusions
MSCs can be expanded in media supplemented with
HPL that can totally replace FBS as well as FGF2. HPL
represents an important tool for clinical use to avoid
animal-derived additives. HPL does not induce major
phenotypical changes. Despite some variations in differ-
entiation markers, MSCs retain their differentiation
capacity toward four mesenchymal lineages. The clear
growth-promoting activity of HPL can be particularly
Azouna et al. Stem Cell Research & Therapy 2012, 3:6
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Page 12 of 14useful to shorten expansion culture duration of human
MSCs to make their clinical-scale production safer.
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